QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=9066F83F093952A2C700D8AE88761875;jsessionid=2EB981516E01CD98213D68F4C966FA78;jsessionid=BA4C4ACDA62A89498DCE2AED5C8694B8;jsessionid=B87BA47DF545C8547A568051182E665E;jsessionid=119BC6976E4D1C529E1B579E038494B2;jsessionid=4458C63AE6D10B4F57BA768588973A8B;jsessionid=3607D8DDB35F9B1D1BC4E2A592A6A6EC (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=0B3561E72662FBE6EB77424C6CF9E852;jsessionid=48FD400854722EAA9233B97BBB9A4283;jsessionid=60238739B2F34634A15F586986642293;jsessionid=9066F83F093952A2C700D8AE88761875;jsessionid=2EB981516E01CD98213D68F4C966FA78;jsessionid=BA4C4ACDA62A89498DCE2AED5C8694B8;jsessionid=B87BA47DF545C8547A568051182E665E;jsessionid=119BC6976E4D1C529E1B579E038494B2;jsessionid=4458C63AE6D10B4F57BA768588973A8B;jsessionid=3607D8DDB35F9B1D1BC4E2A592A6A6EC